Gsa Capital Partners LLP Vista Gen Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.12 - $0.3 $458,416 - $1.15 Million	-3,820,139 Reduced 74.97%	1,275,215 $153,000
Q4 2022 Feb 13, 2023	SELL	$0.09 - $0.16 $11,424 - $20,310	-126,938 Reduced 2.43%	5,095,354 $525,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $1.07 $711,809 - $5.44 Million	5,084,354 Added 3685.97%	5,222,292 $794,000
Q2 2022 Aug 09, 2022	BUY	$0.88 - $1.73 $56,292 - $110,666	63,969 Added 86.48%	137,938 $121,000
Q1 2022 May 11, 2022	BUY	$1.14 - $2.09 $84,324 - $154,595	73,969 New	73,969 $92,000

Q4 2021 Feb 14, 2022	SELL	$1.67 - $2.76 $53,413 - $88,275	-31,984 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$2.62 - $3.45 $83,798 - $110,344	31,984 New	31,984 $88,000

2.7M

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $720M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.